المؤلفون: Pappalardi, M. B., Keenan, K., Cockerill, Mark, Kellner, W. A., Stowell, Alexandra, Sherk, C., Wong, K., Pathuri, S., Briand, J., Steidel, M., Chapman, Philip, Groy, A., Wiseman, A. K., McHugh, C. F., Campobasso, N., Graves, A. P., Fairweather, E., Werner, T., Raoof, Ali, Butlin, Roger J, Rueda, L., Horton, J. R., Fosbenner, D. T., Zhang, C., Handler, J. L., Muliaditan, M., Mebrahtu, M., Jaworski, J. P., McNulty, D. E., Burt, Charlotte, Eberl, H. C., Taylor, A. N., Ho, T., Merrihew, S., Foley, S. W., Rutkowska, A., Li, M., Romeril, S. P., Goldberg, Kristin, Zhang, X., Kershaw, Christopher S, Bantscheff, M., Jurewicz, A. J., Minthorn, E., Grandi, P., Patel, M., Benowitz, A. B., Mohammad, H. P., Gilmartin, A. G., Prinjha, R. K., Ogilvie, Donald, Carpenter, C., Heerding, D., Baylin, S. B., Jones, P. A., Cheng, X., King, B. W., Luengo, J. I., Jordan, Allan M, Waddell, Ian D, Kruger, R. G., McCabe, M. T.

المساهمون: Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA

Relation: Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002-17.; http://hdl.handle.net/10541/624970; Nature Cancer

الاتاحة: http://hdl.handle.net/10541/624970